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Plasma immunoreactive ,8-melanocyte stimulating hormone (,8-MSH) has been measured 
in patients taking a progestogen-only oral contraceptive and in patients taking combined 
estrogen- progestogen therapy, of whom some had chloasma. Plasma levels did not differ 
significantly from those in a group of age- and sex-matched controls. It is concluded that the 
pigmentation of chloasma is not due to increased plasma concentrations of immunoreactive 
,8-MSH. 
Increased plasma concentrations of immuno-
reactive ,8-MSH are associated with skin melani-
zation in Addison's disease and Cushing's syn-
drome 11 ,2) and chronic renal failure [3-5). We 
wondered whether a similar association might ex-
plain the chloasma of oral contraceptive therapy. 
MATERIALS AND METHODS 
Forty-five patjents taking oral contraceptives were 
studied. Fourteen were taking a progestogen-only prep-
aration (Lynestrenoll and 31 were taking various com-
bined estrogen and progestogen preparations. Of the 
latter 17 had chloasma. A control group of 16 age-
matched women not taking oral contraceptives was also 
studied. 
Plasma immunoreactive ~-MSH was measured by a 
modification of the method of Thody and Plummer [2]. 
,B-MSH was thought to be the major MSH peptide in 
man but is now believed to only occur naturally as part 
of the larger lipotropin molecules (LPH) [6). These hor-
mones cross react in existing immunoassays [7] and so 
our method probably measures a mixture of ~- and y-
LPH. While these doubts exist about its chemical na-
ture it seems best to refer to what we are measuring as 
immunoreactive ~-MSH. 
RESULTS 
The results are shown in the Figure. The mean 
<:::SEM) plasma immunoreactive ,B-MSH levels in 
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patients on progestogen-only therapy was 10.8 ± 
1.5 pg/rnl; for patients on combined estrogen and 
progestogen therapy without chloasma. 11.6 ± 
2.6 pg/ml; and for those on combined estrogen and 
progestogen therapy with chloasma. 10.3 ± 1.8 pg/ 
ml. None of these levels differed significantly from 
the 13.5 ± 1.8 pg/mJ (range 4-25 pg/ml) obtained 
from the age- and sex-matched controls. 
DlSCUSSlON 
In this study. patients taking oral contracep-
tives. including 17 with chloasma, were found to 
have normal plasma immunoreactive ,8-MSH lev-
els. Clearly. elevation of immunoreactive ,8-MSH 
plays no part in the pathogenesis of the chloasma 
of oral contraceptive therapy. We have previously 
shown that plasma immunoreactive ,8-MSH con-
cent rations are normal in late pregnancy [8] and 
so the similar chloasma of pregnancy is likewise 
not due to increased plasma immunoreactive ,8-
MSH levels. 
It seems likely that the localized pigmentation 
of chloasma may be due to a direct effect of certain 
steroid hormones on melanogenesis in predisposed 
clones of melanocytes. Thus the melanogenesis 
which estrogens induce in guinea pigs 19] is maxi-
mal in the areolae. In the presence of progesterone 
a synergistic effect occurs [1 0]. Progesterone also 
causes melanosome dispersal in frog melano-
phores, and this effect is potentiated by MSH 111], 
but whether the normal plasma levels of immuno-
reactive ,8-MSH contribute to the development of 
chloasma by such synergism is unknown. 
We have found immunoreactive ,8-MSH to be 
normal in a wide range of situations associated 
with pigmentation, e.g., pregnancy, phenothia-
zine therapy, liver disease, systemic sclerosis, and 
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FIG. Plasma immunoreactive {3-MSH concentrations 
in (A l normal female controls, (B l patients on progesto-
gen-only therapy. {C) patients on combined estrogen-
progestogen therapy without chloasma. and (D) pa-
tients on combined estrogen- progestogen therapy with 
chloasma. 
cachexia. Pigmentation appears to be associated 
with elevated plasma immunoreactive ,8-MSH 
only in Addison's disease. Cushing's syndrome (in-
cluding ectopic MSH/ACTH producing tumors) 
and chronic renal failure. and in these conditions 
the plasma immunoreactive ,8-MSH concentra-
tions are greatly above the normal range. There is 
thus no evidence that immunoreactive ,8-MSH is a 
pigmentary hormone in the physiologic state. The 
present fmdings and our previous observations 
likewise suggest that its role in pathologic pig-
mentation is limited. 
We wish to thank the physicians who sent us plasma 
samples from patients with chloasma. 
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